Compare QURE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QURE | IVA |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | Netherlands | France |
| Employees | 248 | 77 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 883.8M |
| IPO Year | 2013 | N/A |
| Metric | QURE | IVA |
|---|---|---|
| Price | $47.51 | $3.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | ★ $45.00 | $16.20 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $2.94 |
| 52 Week High | $71.50 | $7.98 |
| Indicator | QURE | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 73.18 | 30.98 |
| Support Level | $21.63 | N/A |
| Resistance Level | $60.70 | $4.67 |
| Average True Range (ATR) | 2.85 | 0.18 |
| MACD | 1.76 | 0.01 |
| Stochastic Oscillator | 87.87 | 10.27 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.